Overview

• The Federal Court of Appeal found that the health minister failed to justify the 2022 denial of exemptions for 93 additional health-care workers and mandated a new decision.
• Therapsil first secured exemptions under the Controlled Drugs and Substances Act in 2020, allowing 19 clinicians to undertake experiential psilocybin training.
• Health Canada has granted over 300 patient exemptions for psilocybin-assisted therapy in recent years, reflecting growing clinical and patient demand.
• Advocates warn that restrictive training policies risk driving practitioners and patients to seek psilocybin outside regulated channels.
• Therapsil says provider firsthand experience with psilocybin is essential for safe therapy guidance and will pursue further litigation if needed.